CL2013000586A1 - Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. - Google Patents
Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.Info
- Publication number
- CL2013000586A1 CL2013000586A1 CL2013000586A CL2013000586A CL2013000586A1 CL 2013000586 A1 CL2013000586 A1 CL 2013000586A1 CL 2013000586 A CL2013000586 A CL 2013000586A CL 2013000586 A CL2013000586 A CL 2013000586A CL 2013000586 A1 CL2013000586 A1 CL 2013000586A1
- Authority
- CL
- Chile
- Prior art keywords
- tgf
- patient
- procedure
- reducing
- myocardial infarction
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title 1
- 239000002876 beta blocker Substances 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37931510P | 2010-09-01 | 2010-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000586A1 true CL2013000586A1 (es) | 2013-08-30 |
Family
ID=44654454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000586A CL2013000586A1 (es) | 2010-09-01 | 2013-02-28 | Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130330352A1 (enExample) |
| EP (1) | EP2611831B1 (enExample) |
| JP (2) | JP6377348B2 (enExample) |
| KR (1) | KR101939965B1 (enExample) |
| CN (1) | CN103201292B (enExample) |
| BR (1) | BR112013004850B1 (enExample) |
| CA (1) | CA2809568C (enExample) |
| CL (1) | CL2013000586A1 (enExample) |
| ES (1) | ES2715177T3 (enExample) |
| IL (1) | IL225018A (enExample) |
| MX (1) | MX354535B (enExample) |
| MY (1) | MY165160A (enExample) |
| NZ (2) | NZ608813A (enExample) |
| PH (1) | PH12013500411A1 (enExample) |
| PL (1) | PL2611831T3 (enExample) |
| RU (1) | RU2637088C2 (enExample) |
| SG (2) | SG10201506909PA (enExample) |
| TR (1) | TR201903101T4 (enExample) |
| WO (1) | WO2012030394A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102395381A (zh) * | 2009-02-18 | 2012-03-28 | 矩阵心血管疾病有限公司 | 用于预防心律失常的组合物和方法 |
| BR112015021595A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| SMT202300027T1 (it) * | 2015-10-30 | 2023-05-12 | Univ California | Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso |
| US9989543B2 (en) | 2016-01-11 | 2018-06-05 | Autotelic, Llc | Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension |
| US20170218040A1 (en) * | 2016-02-02 | 2017-08-03 | Julio A. Camarero Palao | Proteolically resistant cyclotides with angiotensin 1-7 like activity |
| WO2018027329A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | TGF-β ANTAGONIST CONJUGATES |
| SI3628049T1 (sl) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
| EP4410816A4 (en) | 2021-09-30 | 2025-11-19 | Peptidream Inc | Peptide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| MXPA06011199A (es) * | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| EP1848424B1 (en) | 2005-01-31 | 2017-04-05 | Mylan Laboratories, Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| EP1850873B1 (en) * | 2005-02-08 | 2018-11-28 | Genzyme Corporation | Antibodies to tgfbeta |
| BRPI1006979A2 (pt) * | 2009-01-26 | 2016-04-12 | Intermune Inc | métodos para tratar infartos agudos do miocárdio e distúrbios associados |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
-
2011
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en not_active Ceased
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
-
2013
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
-
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000586A1 (es) | Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. | |
| NO20210424A1 (no) | Fremgangsmåte for å utføre brønnoperasjoner | |
| BRPI0910307A2 (pt) | inibidores de hiv integrase | |
| DK3419208T3 (da) | Fremgangsmåde til diskontinuerlig modtagelsesdrift for long-term-evolution-advanced-bæreraggregering | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| ME03376B (me) | Makrociklička jedinjenja kао inhibiтori trk kinaze | |
| EP2603600A4 (en) | PEPTIDOMIMETIC MACROCYCLES | |
| EP2346734A4 (en) | ACTIVE WINGLET | |
| EP3738544C0 (de) | Dentalimplantat | |
| LT3023102T (lt) | Ibat inhibitoriai, skirti kepenų ligų gydymui | |
| IT1394860B1 (it) | Composti farmaceutici | |
| CO6781493A2 (es) | Inhibidores de la faah | |
| HRP20161771T1 (hr) | Formulacije bendamustina | |
| EP2411563A4 (en) | IMPROVED CATHODE | |
| FR2960763B1 (fr) | Implant de suture | |
| CR20140068A (es) | Una formulación herbicida mejorada | |
| EP2563127A4 (en) | PROLYLCARBOXYPEPTIDASE INHIBITORS | |
| SMT201600004B (it) | Coniugato cristallino di naloxolo-peg | |
| ZA201102620B (en) | Hiv integrase inhibitors | |
| IT1393930B1 (it) | Composti farmaceutici | |
| SMT201700122B (it) | Dispositivo per la preparazione di una bevanda | |
| IT1399637B1 (it) | Procedimento per preparare una composizione di silice-allumina amorfa e relativa composizione di silice-allumina amorfa | |
| EP2578161A4 (en) | ULTRASOUND DEVICE | |
| EP2557088A4 (en) | PHYSIOLOGICALLY ACTIVE PEPTIDES | |
| IT1398202B1 (it) | Macchina per la preparazione di una bevanda |